title: Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction.
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficacy of nebivolol, carvedilol or metoprolol succinate on the outcome of patients presenting with acute myocardial infarction (AMI) complicated by left ventricular dysfunction.
  
  
  METHODS
  Patients (n = 172, aged 28-87 years) with AMI and left ventricular ejection fraction ≤0.45 were randomized to the nebivolol (n = 55), carvedilol (n = 60) and metoprolol succinate (n = 57) groups. Baseline demographic and clinical characteristics and composite event rates of nonfatal MI, cardiovascular mortality, hospitalization due to unstable angina pectoris or heart failure, stroke or revascularization during the 12-month follow-up were compared among the groups using the x03C7;2 test, t test or log-rank test as appropriate.
  
  
  RESULTS
  Baseline demographic and clinical characteristics were similar in the three groups. The composite end point during follow-up was lower in the patients treated with nebivolol than those treated with metoprolol (14.5 vs. 31.5%; p = 0.03). However, event rates were similar between the patients treated with carvedilol and those treated with the metoprolol (20.3 vs. 31.5%, p > 0.05) and between the patients treated with nebivolol and carvedilol (14.5 vs. 20.3%, p > 0.05).
  
  
  CONCLUSIONS
  The patients treated with nebivolol experienced 12-month cardiovascular events at a lower rate than those treated with metoprolol succinate. However, event rates were similar between the carvedilol and the metoprolol succinate groups and between the nebivolol and the carvedilol groups.
authors.affiliation: Department of Cardiology, Suleyman Demirel University, Isparta, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ozaydin
authors.forename: Habil
authors.initials: H
authors.lastname: Yucel
authors.forename: Sule
authors.initials: S
authors.lastname: Kocyigit
authors.forename: Mehmet Koray
authors.initials: MK
authors.lastname: Adali
authors.forename: Fatih
authors.initials: F
authors.lastname: Aksoy
authors.forename: Fatih
authors.initials: F
authors.lastname: Kahraman
authors.forename: Bayram Ali
authors.initials: BA
authors.lastname: Uysal
authors.forename: Dogan
authors.initials: D
authors.lastname: Erdogan
authors.forename: Ercan
authors.initials: E
authors.lastname: Varol
authors.forename: Abdullah
authors.initials: A
authors.lastname: Dogan
mesh_terms: D058665:Adrenergic beta-1 Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D005260:Female; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000401:mortality; D000068577:Nebivolol / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use; D016037:Single-Blind Method; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000453:epidemiology* / Q000401:mortality
chemical_list: D058665:Adrenergic beta-1 Receptor Agonists; D002227:Carbazoles; D011412:Propanolamines; D000068577:Nebivolol; D000077261:Carvedilol; D008790:Metoprolol